Trilaciclib
Trilaciclib is an orally bioavailable, short-acting CDK4/6 inhibitor (IC50 1-4 nM) that induces reversible G1 arrest. It is researched for mitigating chemotherapy-induced myelosuppression and enhancing antitumor immunity in various cancers, with applications in both in vitro cell cycle studies and in vivo preclinical models.
Product Specifications
CAS Number
1374743-00-6
Product Name Alternative
CDK6, CDK4, Trilaciclib
Field of Research
Cell Biology, Pharmacology & Drug Discovery
Purity
99.62% (May vary between batches)
Solubility
DMSO:4.5 mg/mL (10.08 mM)
Smiles
CN1CCN (CC1) c1ccc (Nc2ncc3cc4C (=O) NCC5 (CCCCC5) n4c3n2) nc1
Molecular Formula
C24H30N8O
Molecular Weight
446.55
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
035635-ML490 100 µL
FGFR1, CT (FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR, Fibroblast growth factor receptor 1, Basic fibroblast growth factor receptor 1, Fms-like tyrosine kinase 2, N-sam, Proto-oncogene c-Fgr, CD331) (MaxLight 490) discontinued
Sign In for Pricing
View Details 
RC210910L3 10 µg
PKC theta (PRKCQ) (NM_006257) Human Tagged Lenti ORF Clone
Sign In for Pricing
View Details 
GTR10314843 96 Well
Guinea Pig Cell differentiation protein RCD1 homolog (RQCD1) ELISA Kit
Sign In for Pricing
View Details NBP2-41287JF549 0.1 mL
Rabbit Polyclonal Parkin Antibody [Janelia Fluor 549]
Sign In for Pricing
View Details